Astronautx

Funding and backers

Total raised
$61M
1 round on record
Latest round
$61M
Series A · Oct 2023 · 3 yr ago
Backers
3
Brandon Capital, MPM BioImpact
The money's age
Long since its last round
37 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 7 Board appointment AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board · PRNewswire Oct 1, 2024 New executive AstronauTx appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team · astronautx.bio Oct 8, 2023 Raised a round Series A $61M
Funding rounds
RoundDateAmountInvestorsSource
Series A Oct 2023 $61M — medindia.net
Backed byfrom the funds' portfolios and accelerator catalogs

Financials

Total raised
$61M
Latest round
Series A
Funding rounds
1
Funding rounds
Round Announced Amount
Series A 2023 $61M Details

Connections

List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors3
MPM BioImpactVia a fund
20 portfolio companies: Umoja Biopharma, Reunion Neuro, Tizona Therapeutics and 17 more
Brandon CapitalVia a fund
25 portfolio companies: Myricx Pharma Limited, Currusbio, Cinceratx and 22 more
30 portfolio companies: SpliceBio, Vivet Therapeutics, Tagworkspharma and 27 more

News

News telegraph.co.uk 1 month ago
View story (Behind paywall)
11 October 2026 The Daily Telegraph View story (Behind paywall)
Read more
Report
News ft.com 1 month ago
View story (Behind paywall)
11 October 2026 The Daily Telegraph View story (Behind paywall)
Read more
Report
News FinanzNachrichten.de 1 month ago
Saniona AB: AstronauTx exercises option from Saniona to acquire worldwide rights to neurological disease program under research collaboration
Development candidate ATX0926 enters IND-enabling stage of development expanding AstronauTx's pipeline of therapies targeting sleep biologyRepresents the successful outcome of a multi-year scientific collaboration
Read more
Report
Award markets.businessinsider.com 2 months ago
AstronauTx awarded research funding from The Michael J. Fox Foundation and Parkinson's UK to explore sleep-based approaches for Parkinson
MJFF grant will support development of a potential disease-modifying treatment for prodromal Parkinson
Read more
Report
Award 2 months ago
AstronauTx awarded research funding from The Michael J. Fox Foundation and Parkinson's UK to explore sleep-based approaches for Parkinson's disease
MJFF grant will support development of a potential disease-modifying treatment for prodromal Parkinson's disease by targeting restorative sleep mechanisms Parkinson's UK-funded research with University College London (UCL) will further explore the link be
Read more
Report
Award YahooFinance 2 months ago
AstronauTx awarded research funding from The Michael J. Fox Foundation and Parkinson's UK to explore sleep-based approaches for Parkinson
MJFF grant will support development of a potential disease-modifying treatment for prodromal Parkinson
Read more
Report
Blog 3 months ago
AstronauTx exercises option from Saniona to acquire worldwide rights to neurological disease program under research collaboration
Development candidate ATX0926 enters IND-enabling stage of development expanding AstronauTx's pipeline of therapies targeting sleep biology Represents the successful outcome of a multi-year scientific collaboration between AstronauTx and Saniona Saniona r
Read more
Report
Blog 4 months ago
Alzheimer's Association International Conference 2026 (AAIC)
Alzheimer's Association International Conference 2026 (AAIC) 12-15 July 2026 London Jane Rhodes, Chief Executive Officer attending event View event website
Read more
Report
Blog 5 months ago
BIO International Convention
BIO International Convention 22-25 June 2026 San Diego Jane Rhodes, Chief Executive Officer Presentation: Wednesday 24 June, 14:00-14:15 PDT, Theater 4 View event website
Read more
Report
Blog 5 months ago
Discovery & Development Europe 2026
Discovery & Development Europe 2026 15-16 June 2026 Berlin Magnus Ivarsson, Chief Scientific Officer "Modulating Sleep As An Entry Point To Treating Neurodegenerative Disorders" presentation Tuesday 16 June 2026, 09:25-09:50 CEST View event website
Read more
Report
Show more news